A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL)

A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL)

IntroductionThe phase III Keynote-189 trial established a first-line treatment combining pembrolizumab with pemetrexed and platinum as a standard treatment for patients with stage IV non-small cell lung cancer (NSCLC) without known EGFR and ALK driver mutations and independent of programmed cell dea...

Full description

Bibliographic Details
Main Authors: Alessandro Cafaro, Flavia Foca, Oriana Nanni, Marco Chiumente, Marina Coppola, Paolo Baldo, Sabrina Orzetti, Fiorenza Enrico, Vito Ladisa, Rosa Lerose, Patrizia Nardulli, Piera Maiolino, Federica Gradellini, Anna Rita Gasbarro, Gisella Carrucciu, Riccardo Provasi, Paola Cristina Cappelletto, Alessandra Pasqualini, Stefano Vecchia, Marianna Veraldi, Adele Emanuela De Francesco, Lucio Crinò, Angelo Delmonte, Carla Masini
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
pembrolizumab
non-small cell lung cancer
real-world data
immunotherapy
observational study
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1351995/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1351995/full

Similar Items